Literature DB >> 2187854

Inhaled PAF fails to induce airway hyperresponsiveness to methacholine in normal human subjects.

C K Lai1, J R Jenkins, R Polosa, S T Holgate.   

Abstract

The effects of three increasing doses of platelet-activating factor (PAF) on airway caliber and methacholine bronchial responsiveness were studied. On separate occasions nine normal subjects inhaled a single cumulative provocation concentration of methacholine (control) causing a 40% fall (PC40 Vp30) in maximum expiratory flow rate at 70% of base-line vital capacity below total lung capacity during a partial forced expiratory maneuver or 100 or 200 micrograms PAF, and seven subjects inhaled a further dose of 400 micrograms PAF. Methacholine responsiveness was measured before, at 3 and 7 h, then on days 1, 2, 3, 4, 7, 10, and 14 after each challenge. The maximum falls in Vp30 appeared dose dependent, but a significant difference between the magnitude of the responses was only observed between the 400- and 100-micrograms PAF dose (P less than 0.05). During the control period repeated methacholine challenges resulted in a progressive increase in cumulative provocation concentration of an agonist causing a 20% fall in forced expiratory volume in 1 s from base line, reaching significance on days 1 and 2 (2.44- and 2.4-fold of base line, respectively, P less than 0.01) before returning to base line on day 7. No difference was seen in methacholine responsiveness after any of the three doses of PAF compared with that after the control. We conclude that PAF causes dose-dependent bronchoconstriction but does not change airways responsiveness to methacholine and that repeated high-dose methacholine challenge leads to loss of responsiveness to this agonist.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2187854     DOI: 10.1152/jappl.1990.68.3.919

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  7 in total

1.  Effect of a 5-lipoxygenase inhibitor and leukotriene antagonist (PF 5901) on PAF-induced airway responses in neonatally immunized rabbits.

Authors:  C M Herd; D Donigi-Gale; T S Shoupe; C P Page
Journal:  Br J Pharmacol       Date:  1992-12       Impact factor: 8.739

Review 2.  PAF. A review of its effects, antagonists and possible future clinical implications (Part II).

Authors:  M Koltai; D Hosford; P Guinot; A Esanu; P Braquet
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

3.  Effect of a platelet activating factor antagonist, WEB 2086, on allergen induced asthmatic responses.

Authors:  A Freitag; R M Watson; G Matsos; C Eastwood; P M O'Byrne
Journal:  Thorax       Date:  1993-06       Impact factor: 9.139

4.  Inhaled budesonide fails to inhibit the PAF-induced increase in plasma leukotriene B4 in man.

Authors:  M M Nieminen; E K Moilanen; M O Koskinen; J I Karvonen; L Tuomisto; T J Metsä-Ketelä; H Vapaatalo
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

5.  Participation of the cysteinyl leukotrienes in the acute bronchoconstrictor response to inhaled platelet activating factor in man.

Authors:  D A Spencer; J M Evans; S E Green; P J Piper; J F Costello
Journal:  Thorax       Date:  1991-06       Impact factor: 9.139

6.  Failure of salmeterol to inhibit circulating white cell responses and bronchoconstriction induced by platelet activating factor.

Authors:  J Spring; S R Johnston; J Seale; P W Ind
Journal:  Thorax       Date:  1992-11       Impact factor: 9.139

7.  Nasal hyperreactivity and inflammation in allergic rhinitis.

Authors:  I M Garrelds; C de G Veld; R G Wijk; F J Zijlstra
Journal:  Mediators Inflamm       Date:  1996       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.